Ningrong Chen PhD , Xin Wei PhD , Gang Zhao PhD , Zhenshan Jia PhD , Xin Fu PhD , Haochen Jiang BS , Xiaoke Xu BSc , Zhifeng Zhao PhD , Purva Singh PhD , Samantha Lessard BA , Miguel Otero PhD , Mary B. Goldring PhD , Steven R. Goldring MD , Dong Wang PhD
{"title":"在小鼠骨关节炎模型中,单剂量热冲击性地塞米松原药可在 15 周内完全缓解关节疼痛","authors":"Ningrong Chen PhD , Xin Wei PhD , Gang Zhao PhD , Zhenshan Jia PhD , Xin Fu PhD , Haochen Jiang BS , Xiaoke Xu BSc , Zhifeng Zhao PhD , Purva Singh PhD , Samantha Lessard BA , Miguel Otero PhD , Mary B. Goldring PhD , Steven R. Goldring MD , Dong Wang PhD","doi":"10.1016/j.nano.2024.102735","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>In this study, we aimed to assess the analgesic efficacy of a thermoresponsive polymeric </span>dexamethasone (Dex) </span>prodrug<span><span> (ProGel-Dex) in a mouse model of osteoarthritis<span> (OA). At 12 weeks post model establishment, the OA mice received a single intra-articular (IA) injection of ProGel-Dex, dose-equivalent Dex, or Saline. Comparing to Saline and Dex controls, ProGel-Dex provided complete and sustained pain relief for >15 weeks according to incapacitance tests. In vivo optical imaging<span><span><span> confirmed the continuous presence of ProGel-Dex in joints for 15 weeks post-injection. According to micro-CT analysis, ProGel-Dex treated mice had significantly lower </span>subchondral bone thickness and medial meniscus bone volume than Dex and Saline controls. Except for a transient delay of body weight increase and slightly lower endpoint liver and </span>spleen weights, no other adverse effect was observed after ProGel-Dex </span></span></span>treatment<span>. These findings support ProGel-Dex's potential as a potent and safe analgesic candidate for management of OA pain.</span></span></p></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Single dose thermoresponsive dexamethasone prodrug completely mitigates joint pain for 15 weeks in a murine model of osteoarthritis\",\"authors\":\"Ningrong Chen PhD , Xin Wei PhD , Gang Zhao PhD , Zhenshan Jia PhD , Xin Fu PhD , Haochen Jiang BS , Xiaoke Xu BSc , Zhifeng Zhao PhD , Purva Singh PhD , Samantha Lessard BA , Miguel Otero PhD , Mary B. Goldring PhD , Steven R. Goldring MD , Dong Wang PhD\",\"doi\":\"10.1016/j.nano.2024.102735\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>In this study, we aimed to assess the analgesic efficacy of a thermoresponsive polymeric </span>dexamethasone (Dex) </span>prodrug<span><span> (ProGel-Dex) in a mouse model of osteoarthritis<span> (OA). At 12 weeks post model establishment, the OA mice received a single intra-articular (IA) injection of ProGel-Dex, dose-equivalent Dex, or Saline. Comparing to Saline and Dex controls, ProGel-Dex provided complete and sustained pain relief for >15 weeks according to incapacitance tests. In vivo optical imaging<span><span><span> confirmed the continuous presence of ProGel-Dex in joints for 15 weeks post-injection. According to micro-CT analysis, ProGel-Dex treated mice had significantly lower </span>subchondral bone thickness and medial meniscus bone volume than Dex and Saline controls. Except for a transient delay of body weight increase and slightly lower endpoint liver and </span>spleen weights, no other adverse effect was observed after ProGel-Dex </span></span></span>treatment<span>. These findings support ProGel-Dex's potential as a potent and safe analgesic candidate for management of OA pain.</span></span></p></div>\",\"PeriodicalId\":19050,\"journal\":{\"name\":\"Nanomedicine : nanotechnology, biology, and medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine : nanotechnology, biology, and medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1549963424000042\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine : nanotechnology, biology, and medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963424000042","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Single dose thermoresponsive dexamethasone prodrug completely mitigates joint pain for 15 weeks in a murine model of osteoarthritis
In this study, we aimed to assess the analgesic efficacy of a thermoresponsive polymeric dexamethasone (Dex) prodrug (ProGel-Dex) in a mouse model of osteoarthritis (OA). At 12 weeks post model establishment, the OA mice received a single intra-articular (IA) injection of ProGel-Dex, dose-equivalent Dex, or Saline. Comparing to Saline and Dex controls, ProGel-Dex provided complete and sustained pain relief for >15 weeks according to incapacitance tests. In vivo optical imaging confirmed the continuous presence of ProGel-Dex in joints for 15 weeks post-injection. According to micro-CT analysis, ProGel-Dex treated mice had significantly lower subchondral bone thickness and medial meniscus bone volume than Dex and Saline controls. Except for a transient delay of body weight increase and slightly lower endpoint liver and spleen weights, no other adverse effect was observed after ProGel-Dex treatment. These findings support ProGel-Dex's potential as a potent and safe analgesic candidate for management of OA pain.
期刊介绍:
The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine.
Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.